Key result
Transplacental digoxin yields no quantitative evidence for ameliorating tachycardia-associated fetal heart failure.
Why the study?
Does transplacental Digoxin therapy improve fetal conditions and alter cytokine levels in fetuses with heart failure associated with fetal tachycardia?
Case-Control
No
Does transplacental Digoxin therapy improve fetal conditions and alter cytokine levels in fetuses with heart failure associated with fetal tachycardia?
This study evaluates the efficacy and cytokine changes associated with transplacental digoxin therapy for fetal heart failure and tachycardia.
Answers are grounded in this paper and cite their sources.
Provides insufficient evidence to support transplacental digoxin for fetal tachycardia-induced heart failure;.
Persistent fetal tachycardia may lead to congestive heart failure, hydrops fetalis, and even fetal/neonatal death. Previous studies revealed that Digoxin represents one of the first-line agents for fetal tachycardia and heart failure with the advantages of high efficiency of placental transportation and low retention [1–4]. Recently, with multiple evaluation systems, we examined the efficacy of transplacental Digoxin therapy in our hospital with a focus on amelioration of the fetal conditions before and after treatment [5].
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2013) conducted a case-control in Fetal heart failure associated with fetal tachycardia. Transplacental Digoxin was evaluated on Amelioration of fetal conditions before and after treatment. Transplacental Digoxin therapy was examined for its efficacy in ameliorating fetal conditions in fetal heart failure associated with fetal tachycardia, though no quantitative results are reported.
Synapse has enriched 10 related papers. Consider them for comparative context: